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Abstract
Oxygen-sensing mechanisms are often dysfunctional in tumours. Oxygen sensing is mediated partly via prolyl hydroxylation. The EglN
prolyl hydroxylases are well characterized in regulating the hypoxia inducible factor  (HIF-) hypoxic response, but also are implicated
in HIF-independent processes. EglN3 executes apoptosis in neural precursors during development and failure of EglN3 developmental
apoptosis can lead to certain forms of sympathetic nervous system tumours. Mutations in metabolic/mitochondrial enzymes (SDH, FH,
IDH) impair EglN activity and predisposes to certain cancers. This is because the EglNs not only require molecular oxygen to execute
hydroxylation, but also equally require the electron donor -ketoglutarate, a metabolite from the Krebs cycle. Therefore EglN enzymes
are considered oxygen, and also, metabolic sensors. -Ketoglutarate is crucial for EglN hydroxylation activity, whereas the metabolites
succinate and fumarate are inhibitors of the EglN enzymes. Since EglN activity is dependent upon metabolites that take part in the Krebs
cycle, these enzymes are directly tied into the cellular metabolic network. Cancer cells tend to convert most glucose to lactate regard-
less of whether oxygen is present (aerobic glycolysis), an observation that was first made by Otto Warburg in 1924. Despite the strik-
ing difference in ATP production, cancer cells might favour aerobic glycolysis to escape from EglN hydroxylation, resulting in the accu-
mulation of oncogenic HIF . and/or resistance to EglN3-mediated apoptosis.
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Introduction
Oxygen-sensing mechanisms enable the cell to adapt to low oxy-
gen environments and are also critical for normal development
and apoptosis. Disruptions of oxygen-sensing pathways can lead
to the development of certain forms of cancer [1–15]. Oxygen
sensing is mediated partly via the EglN hydroxylases (EglN1/
EglN2/EglN3) that are dependent upon molecular oxygen, iron (II)
and -ketoglutarate to perform proline hydroxylation on their target
[16–20]. Therefore these enzymes are considered oxygen and also
metabolic sensors. The availability of molecular oxygen is absolutely
required for the hydroxylation reaction, because it donates the 
oxygen atom to the hydroxyl group [21]. But equally important for
the hydroxylation reaction is the electron donor -ketoglutarate, a
metabolite from the Krebs cycle. Since EglN is dependent upon
metabolites that take part in the Krebs cycle, they are directly tied into
the cellular metabolic network (Fig. 1).
The first identified substrate for the EglN prolyl hydroxylases is
the transcription factor hypoxia inducible factor  (HIF-) [16,
17]. The identification of HIF- as a direct hydroxylation substrate
provided the first and direct link between tumour suppressor func-
tion and oxygen sensing. The tumour suppressor von Hippel
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Lindau (VHL) acts as an ubiquitin ligase by targeting hydroxylated
HIF- for degradation when oxygen is available, as where under
low oxygen environments, HIF- escapes hydroxylation and sub-
sequently escapes VHL recognition [3–5, 16, 22–27]. The escape
from VHL recognition allows HIF- to accumulate and to transac-
tivate its target genes that are important for adaptation to low oxy-
gen environment including energy metabolism and angiogenesis
[28–30]. Both HIF-dependent and HIF-independent VHL functions
contribute to VHL-defective tumorgenesis [31–34]. The VHL dis-
ease is caused by inactivating germline mutations of the VHL gene
and predisposes to a variety of tumours including haemangioblas-
toma of the retina and nervous system, clear cell renal carcinomas
(RCC; the most common form of kidney cancer) and phaeochro-
mocytomas/paragangliomas, tumours of the sympathoadrenal
nervous system. HIF- deregulation appears to have a causal role
in VHL-defective clear cell RCC and in VHL-defective blood vessel
tumours haemangioblastomas (HB) [33]. Although HIF- regulation
has been a major focus of VHL research, the genotype–phenotype
correlation in the VHL disease gave insight into HIF-independent
VHL function (Table 1). Specific VHL germline mutations corre-
sponding to a specific subset of tumour phenotypes have a different
relationship to HIF- deregulation (categorized in type I/IIA/IIB/IIC
disease) [35–37]. The type I disease associates with RCC and HB,
and their tumours reflect deregulated high HIF- expression,
whereas a very different clinical outcome is observed in the type
2C-VHL disease. The type 2C disease does not develop RCC and
HB instead develops phaeochromocytomas only. More impor-
tantly, HIF- is not deregulated and maintains in low levels in the
type 2C tumours [31, 32]. These findings suggest that HIF- dereg-
ulation is not necessary for phaeochromocytma development in
VHL disease.
Interestingly, a second hydroxylation target of the prolyl
hydroxylases EglN has recently been identified [38]. The 2-
adrenergic receptor is a prototypic G protein-coupled receptor,
which is hydroxylated by EglN3 and also oxygen dependent
degraded by pVHL. The discovery of another hydroxylation sub-
strate by the EglN enzymes not only broadens the functionality of
prolyl hydroxylation, but also expands our understanding of cellu-
lar response to oxygen and its relationship to disease.
Therefore, the identification of other EglN substrates and the
clues from the genotype–phenotype correlation that emerged in
the VHL disease clearly indicates HIF-independent VHL functions.
Of great insights are studies from EglN3-mediated neuronal apop-
tosis during sympathetic neuronal development, which shed light
onto the genesis of phaeochromocytoma by presumably HIF-
independent pathways [9].
Lessons from a rare disease
Phaeochromocytomas are rare, with only five to eight cases 
diagnosed per million people a year [39]. They are neoplasias 
of neural crest origin arising from the adrenal medulla.
Phaeochromocytomas can also develop in extra-adrenal sympa-
thetic ganglia 10% of the time. Extra-adrenal phaeochromocy-
tomas are sometimes referred to as paragangliomas [40]. In
short, these tumours are sympathetic nervous system tumours.
The predisposing germline mutations lend clues to the patho-
genesis of this disease. The most frequent causes of phaeochro-
mocytoma susceptibility are VHL missense mutations, activating
Fig. 1 Schematic representation of the
EglN prolyl hydroxylase catalytic action.
EglN prolyl hydroxylases (also referred
to as PHD) belong to the 2-oxoglutarate-
dependent oxygenase superfamily. The
requirement of dioxygen as cosubstrate
demonstrates function in cellular oxygen
sensing. Two histidine residues at the
catalytic site coordinate a non-heme
iron. The reaction proceeds via the
incorporation of dioxygen into the prolyl
residue forming hydroxyproline at the
substrate. As electron donor for this
reaction serves -ketoglutarate (2-
oxoglutarate) which is oxidized to succi-
nate and CO2. The dependency of the
metabolite  -ketoglutarate for catalytic
activity makes these enzymes sensitive
to -ketoglutarate levels and ties them
directly into the metabolic network.4106 © 2009 The Author
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
mutations in c-Ret, mutations in neurofibromatosis type 1 (NF1)
and mutations in succinate dehydrogenase subunits of mito-
chondrial complex II (SDH B/C/D). Loss of NF1 has been
reported to promote survival of embryonic sympathetic neurons
in the absence of the nerve growth factor NGF [41]. Further,
mutations in subunits of mitochondrial complex II suggest
impairment of mitochondria-mediated apoptosis and have led to
the early hypothesis that failure of apoptosis in neuroendocrine
precursor cells could result in the development of phaeochromo-
cytoma and paraganglioma [40]. Given the evidence that NF1
promotes sympathetic neuronal survival and further that these
neoplasias originate from the sympathetic nervous system, a
closer look into the sympathetic neuronal development reveals
important clues to the genesis of these tumours [9].
Since the discovery by Rita Levi-Montalcini and Viktor
Hamburger of the neurotrophic factor NGF, our understanding
of developmental apoptosis in the sympathetic nervous system
has greatly increased [42]. During neuronal development, NGF
is required for survival but is also limiting. Neurons that suc-
cessfully compete for NGF during development survive
whereas unsuccessful neurons die. Competition for NGF is an
important developmental process for matching the size of a
neuronal population, especially in the peripheral nervous sys-
tem [43]. As much as 50% of neurons produced during
embryogenesis die by apoptosis during neuronal development.
Abnormal NGF signalling has been linked to paediatric nervous
system tumours such as neuroblastoma [44, 45] and disease-
associated mutations such as NF1 have been shown to enhance
signalling by NGF receptors and promote neuronal survival in
the absence of NGF [41]. In the last decades it became evident
that JNK/c-Jun signalling is required for apoptosis when NGF
is limiting in the developing nervous system [46–50].
Interestingly, the prolyl hydroxylase EglN3 has recently been
implicated in this pathway. EglN3 is induced in sympathetic
neurons deprived of NGF and further has pro-apoptotic activity
when overexpressed [51]. Given that EglN3 is known to
hydroxylate HIF- and has been implicated in developmental
apoptosis in sympathetic neurons, the following questions
arise: (i ) Does EglN3-mediated apoptosis depend upon its
hydroxylation activity? (ii ) Does it depend upon HIF hydroxy-
lation or does it involve hydroxylation of unknown substrates?
(iii ) Is failure of EglN3-mediated apoptosis implicated in the
genesis of phaeochromocytomas and other tumours arising
from the neural crest origin?
Specificity of function within the EglN
prolyl hydroxylases
The ability of EglN3 to induce neuronal apoptosis appears to be
unique among the EglN family members [9]. Induction of apoptosis
is dependent upon EglN3 hydroxylation activity, because catalytic
impaired EglN3 fails to induce apoptosis [9, 52]. Importantly,
EglN3-induced apoptosis is not diminished in the presence of sta-
ble HIF1 or HIF2 variants that cannot be hydroxylated on their
prolines [9]. This suggests that hydroxylation targets of EglN3
other than HIF- are crucial for apoptosis function.
EglN2 and EglN3 are induced by hypoxia and dampen the HIF-
response under chronic hypoxia [53–57]. However, EglN1 appears
to be the primary HIF prolyl hydroxylase under normal conditions
[58]. Consistent with this, mice lacking EglN2 or EglN3 are viable
and grossly normal whereas mice lacking EglN1 are not viable
[59]. Conditional inactivation of EglN1 in mice leads to poly-
cythemia due to HIF- stabilization and increased transcription of
HIF target genes including erythropoietin [60, 61]. Further,
patients carrying EglN1 mutations have been reported to develop
polycythemia concluding that EglN1 couples HIF- stability in vivo
[13, 62, 63].
Consistent with the unique role of EglN3 in neuronal apoptosis
are studies obtained from the EglN3-deficient mice that clearly
demonstrates the requirement for EglN3-mediated apoptosis dur-
ing the sympathetic neuronal development. EglN3 deficient sym-
pathetic neurons are resistant to apoptosis after NGF withdrawal,
as well as certain neurotoxins [64]. Consistently, EglN3
–/– mice
have an increased number of cells in the super cervical ganglia
and in the adrenal medulla and show abnormalities in the sympa-
thoadrenal system including systemic hypotension [65]. In fact, it
appears that some of the adrenal abnormalities are caused
through deregulation of the 2-adrenic receptor (2-AR) [38].
EglN3 specifically hydroxylates 2-AR, whereas EgN1 and EglN2
fail to do so. This leads to subsequent ubiquitination and degradation
mediated by pVHL. Loss of EglN3 results in 2-AR up-regulation
and accordingly, hypoxia stabilizes the 2-AR. This is consistent
with the observations from the type 2C VHL patients that develop
phaeochromocytoma. Type 2C patients often show excessive
secretion of catecholamines (endogenous 2-AR ligands) and
increased sympathonervous system activity [66].
In summary, this points towards distinct and unique functions
within the family of EglN prolyl hydroxylases. Identification of
Table 1 Genotype–phenotype correlation in the VHL disease
Type Mutation Manifestation HIF-
I Loss of VHL function: loss, truncated or missfolded Haemangioblastoma, Renal cell carcinom
↓
II A/B VHL missense mutations Haemangioblastoma, Renal cell carcinom and phaeochromocytoma
↓
II C VHL missense mutations Phaeochromocytoma only ↓J. Cell. Mol. Med. Vol 13, No 10, 2009
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novel EglN hydroxylation targets will open new oxygen sensing
pathways independent of what we have learned from HIF-.
Failure of EglN3-mediated apoptosis 
in the genesis of phaeochromocytoma
Given the evidence that (i) phaeochromocytomas are sympathetic
nervous system tumours and that (ii) EglN3 is critical for apoptosis
during sympathetic neural development, an attractive hypothesis
emerged in which failure of EglN3-mediated apoptosis during
sympathetic development predisposes to the genesis of
phaeochromocytomas and perhaps other neoplasia arising from
neural crest origin [9]. Interestingly, apparently unlinked
phaeochromocytoma lesions (VHL,  NF1,  c-RET and  SDH) all
appear to act on a single common pathway by decreasing EglN3-
mediated apoptosis at the time during development when levels of
NGF become limiting (Fig. 2) [9]. During this developmental win-
dow, the sympathetic precursors undergo c-Jun-dependent apop-
tosis [67–70]. EglN3 appears to act downstream of the c-Jun in
the NGF signalling pathway [9]. Therefore, a single pathway was
established in which the genetic phaeochromocytoma defects act
either directly on EglN3 or upstream of EglN3 to impair apoptosis
(Fig. 2). For instance, the genetic defect in SDH acts directly on
EglN3-mediated apoptosis function. SDH inhibition results in
accumulation of intracellular succinate, which in turn can product-
inhibit the EglN prolyl hydroxylases [9, 71]. This succinate-
mediated inhibition not only results in HIF stabilization, but also
importantly inhibits EglN3-mediated apoptosis. Further, SDH inhi-
bition blunts neuronal apoptosis when NGF is limiting [9]. The
succinate-mediated product-inhibition of EglN3 was overcome by
re-addition of -ketoglutarate restoring NGF-mediated apoptosis
[9]. This suggests that SDH inhibition acts on the prolyl hydroxy-
lases via succinate and not as alternatively suggested through the
generation of reactive oxygen species.
In addition to the predisposing SDH genetic lesion, other
phaeochromocytoma lesions have been implicated upstream of
EglN3 to promote neuronal survival in the NGF signalling path-
way. In the case of VHL predisposing lesion, loss of pVHL pro-
motes survival through up-regulation of JunB. pVHL suppresses
JunB and all VHL mutants tested (including type IIC VHL disease
mutant) abrogate its ability to do so [9]. JunB acts as an antag-
onist of c-Jun and increased JunB levels attenuate the induction
of c-Jun-mediated apoptosis in sympathetic neurons deprived
from NGF.
Finally, previous evidence indicated that RET (the receptor for
glial-derived neurotrophic factor) and NF1 could act through this
pathway by modulating the action of the NGF receptor TrkA. Loss of
NF1 promotes NGF-independent survival of embryonic peripheral
neurons [41]. In addition, c-RET can crosstalk with the NGF recep-
tor TrkA [72]. Activation of c-Ret, like loss of pVHL, leads to the
induction of JunB and attenuates apoptosis when NGF becomes
limiting [9].
Thus, when mutated, all the genetic phaeochromocytoma
lesions (SDH,  VHL,  c-RET and  NF1) impair NGF-mediated
apoptosis in neuroendocrine precursors during development.
These findings provide an explanation as to why the mutations
in tumour suppressors that are found in familial phaeochromo-
cytoma are rare in sporadic phaeochromocytoma. This is
because the pathway is no longer critical once development 
is completed.
In summary, all the genetic lesions associated with phaeochro-
mocytoma act on a single common pathway that impinges upon
EglN3 apoptotic activity during sympathetic neuronal develop-
ment. Mutations in SDH, VHL, c-RET and NF1 would allow sym-
pathetic neuronal precursors to escape from developmental apop-
tosis and set the stage for their neoplastic transformation. It will
be interesting to determine not only if EglN3 is mutated in these
neoplasias, but also, if failure of EglN3 developmental apoptosis
plays a broader role in paediatric cancers and other forms of
hereditary cancer.
Fig. 2 Model linking familial phaeochromocytoma genes to NGF-depend-
ent apoptosis. During sympathetic neuronal development, NGF is
required for neuronal survival but is also limiting. Neurons that success-
fully compete for NGF survive whereas unsuccessful neurons undergo 
c-Jun-dependent apoptosis. C-Jun transcriptionally activates prolyl
hydroxylase EglN3. As NGF levels become limiting, familial phaeochro-
mocytoma mutations (VHL, NF1, c-RET, SDH and KIF1B) all decrease
apoptosis mediated by EglN3.4108 © 2009 The Author
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Understanding the mechanistic basis
of EglN3 killing
EglN3-mediated apoptosis is hydroxylation dependent, but inde-
pendent of HIF- hydroxylation [9]. An important challenge is to
identify the link between this enzyme and apoptosis, which pre-
sumably involves hydroxylation of a protein other than HIF-.
Early studies indicated that EglN3 mRNA and protein expres-
sion (at that time referred as SM-20) increases shortly after
removal of NGF in primary sympathetic neurons and peaks
between 10 and 15 hrs at a time when cells undergo apoptosis
[51]. Overexpression of EglN3 is sufficient to promote cell death
in NGF-maintained sympathetic neurons [51, 73]. Cell death is
caspase dependent and accompanied by an increase of
cytochrome c in cytosolic and mitochrondria-enriched subcellular
fractions [74]. The mechanism underlying EglN3-induced
cytochrome c is not known although it appears to involve an
increase in cytochrome c mRNA. Other studies have identified
EglN3 as a growth factor inducible gene in vascular smooth mus-
cle cells [75] and later proposed, that it might function in growth
arrest, differentiation and cell death during muscle differentiation
[76, 77]. Expression of EglN3 was also reported in fibroblasts
upon activation of a temperature-sensitive form of p53 [78].
However, EglN3-induced apoptosis appears not to be impaired in
cells lacking p53 or expressing a dominant negative p53 protein,
indicating that p53 might not function downstream of EglN3 to
induce apoptosis [9]. In addition, a recent study indicated that
EglN3’s ability to induce apoptosis correlates with the formation of
aggresome-like structures [52].
Recently, an unbiased genome-wide approach has been under-
taken to understand how EglN3 causes neuronal cell death. A
short interference RNA library was used to identify genes that sup-
press EglN3-induced apoptosis [64]. This led to the identification
of the kinesin KIF1B as a downstream effector of EglN3. KIF1B,
a member the kinesin 3 family, consists of two major splice vari-
ants  and . KIF1B and KIF1B are motor proteins implicated
in anterograde transport of mitochondria and synaptic vesicle pre-
cursors, respectively [79, 80]. The recent study, which identified
KIF1B as an EglN3 downstream target showed how KIF1B is
both necessary and sufficient for neuronal apoptosis when NGF
becomes limiting, but it remained unclear how EglN3 regulates
KIF1B [64]. Interestingly, KIF1B maps on to the chromosomal
region 1p36.2, a region of the genome that is frequently deleted in
neural crest-derived tumours including neuroblastomas [81]. The
existence of one or more human tumour suppressor genes on
chromosome 1p has been suspected for decades [82–84]. Further
suggestion that KIF1B acts as a 1p36 tumour suppressor comes
from the current model for phaeochromocytoma development.
Phaeochromocytomas develop when sympathetic neuronal pre-
cursors escape from EglN3-mediated developmental apoptosis,
suggesting that mutations in KIF1B may be relevant to
phaeochromocytoma and other tumours of neuronal origin.
Indeed, inherited loss-of-function KIF1B missense mutations
have been identified in phaeochromocytomas and neuroblastomas
and an acquired loss-of function mutation in a medullablastoma,
arguing that KIF1B is a pathogenic target of these deletions [64].
Nonetheless, it has been further reported that the remaining
KIF1B allele in 1p deleted tumours and cell lines is often wild-
type, contrary to the Knudson TwoHit scenario [64, 85–88].
Perhaps KIF1B haploinsufficiency is adequate for tumorgenesis
in some contexts. Also, the existence of multiple neuroblastoma
and phaeochromocytoma suppressor genes on 1p has been sug-
gested [89, 90]. Additional studies are needed to address how
often it is deregulated, epigenetically or genetically, in cancer. A
spotlight is now on understanding the mechanistic basis of how
EglN3 regulates KIF1B and how this translates into cell death.
KIF1B appears not be a direct EglN3 hydroxylation target, but
EglN3 hydroxylation activity is required for KIF1B regulation.
Therefore EglN3 presumably involves hydroxylation of a protein
that in turn might regulate KIF1B to induce apoptosis.
Connecting EglN activity 
to the Warburg conundrum
In 1924, Otto Warburg observed that cancer cells are highly gly-
colytic in the presence of oxygen and have reduced rates of oxida-
tive phosphorylation [91]. Recent studies have argued that cancer
cells might benefit from this persistence of high lactate production
in the presence of oxygen, referred to as aerobic glycolysis or
pseudo-hypoxia [92, 93]. From a bioenergetic perspective, it
remains a conundrum how highly metabolic proliferative cancer
cells undergo a pathway that results in 10 times less ATP produc-
tion compared to their normal counterparts that oxidize their gly-
colysis endproduct within the mitochondria via the Krebs cycle
(pyruvate conversion into Acetyl-CoA, Fig. 3). Interestingly, three
major enzymes of the Krebs cycle (SDH, FH, IDH) have been
recently identified as bonafide tumour suppressors, but more
importantly, inactivation in either of them directly affects EglN
activity [9, 10, 14, 71]. This is because the EglN activity is not only
dependent upon molecular oxygen to perform their hydroxylation
reaction, but also require the Krebs cycle metabolite -ketoglu-
tarate as electron donor, which ties them directly into this meta-
bolic network. Therefore an attractive hypothesis arises: cancer
cells favour aerobic glycolysis to inhibit EglN activity in order to
escape either certain oncogenic apoptotic signals and/or activate
oncogenic HIF-. About 70% or more of low-grade gliomas bear
loss of function mutation in IDH1 and IDH2 [94, 95]. Loss of func-
tion mutation in IDH1 results in a decrease of intracellular 
-ketoglutarate. Subsequently EglN prolyl hydroxylases are inhib-
ited in their hydroxylase activity with the consequences of HIF-
stabilization [14]. Presumably EglN3-mediated apoptosis might be
impaired in these settings as well, but this has not been investi-
gated yet. Further, these studies follow the discoveries that
germline mutation in SDH are linked to phaeochromocytoma and
that FH mutation lead to leiomyosarcoma and renal cell carcinoma,
both of which affect also the EglN prolyl hydroxylase activity 
[9, 10, 71]. This is because loss of function mutation in SDH andJ. Cell. Mol. Med. Vol 13, No 10, 2009
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FH increases the accumulation of succinate and fumarate respec-
tively. The excess of these metabolites inhibits the proline hydrox-
ylases with the consequences in either accumulation of oncogenic
HIF- and/or blunting EglN3-mediated apoptosis [9, 10, 71, 96].
Future directions
The recently identified mutations in the metabolic/mitochondrial
enzymes (FH, SDHB/C/D, IDH1/2) provide convincing evidence that
alteration in cellular metabolism contributes to the pathogenesis of
cancer. Hence, 43 years later we are beginning to learn the depth of
Otto Warburg’s foresight that (in his words) ‘cancer cells should be
interpreted as a mitochondrial dysfunction’ and that ‘the prime
cause of cancer is the replacement of the respiration of oxygen in
normal body cells by a fermentation of sugar’ [97, 98]. Even if this
is the prime cause for some cancers, the underlying mechanistic
basis remains controversial. However, recently it has become more
evident that the inactivation of the EglN prolyl hydroxylases is a
downstream effector of these mitochondrial alterations.
Consequently, EglN inhibition results in activation of oncogenic
HIF and/or blunting EglN3-mediated apoptosis. The identification
of SDH and FH mutations has already led to the development of cell
permeable -ketoglutarate derivates with the potential to suppress
the transforming effects of these mutations through reactivation of
the EglNs [99]. The exciting part of identifying metabolic-enzyme
mutations in specific cancers is that they are ‘druggable’. They
Fig. 3 The Krebs cycle enzymes (SDH, FH and IDH ) are tumour suppressors and linked to EglN activity. Inactivation of metabolic enzymes SDH, FH or
IDH directly affects EglN activity. The EglN prolyl hydroxylases are dependent upon the Krebs cycle metabolite -ketoglutarate as electron donor for
hydroxylation activity. Loss of function mutation in IDH decreases -ketoglutarate levels and subsequently impairs EglN function. On the other hand,
mutation in SDH or FH leads to accumulation of succinate or fumarate respectively, which in turn product-inhibits EglN activity. Loss of function of SDH,
FH or IDH would lead to impaired Krebs cycle activity and impaired oxidative phosphorylation with the consequence of enhanced glycolysis
(Embden–Meyerhof pathway) to generate ATP. The generated pyruvate during glycolysis is redirected away from the Krebs cycle by conversion into lac-
tate. Cancer cells tend to convert most glucose to lactate regardless of whether oxygen is present (aerobic glycolysis), an observation that was first
made by Otto Warburg in 1924. Despite the striking difference in ATP production, cancer cells might favour aerobic glycolysis to escape from EglN
hydroxylation, resulting in the accumulation of oncogenic HIF . and/or resistant to EglN3-mediated apoptosis.4110 © 2009 The Author
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
might provide new opportunities as therapeutic targets that would
be more susceptible and more effective than existing cancer thera-
pies. Future work is needed to further elucidate the direct impact of
cancer metabolism in prolyl hydroxylase functioning.
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